Form 4: Thermo Fisher Scientific CFO Stephen Williamson Reports Adjustment in Performance-Based Restricted Stock Units

Stephen Williamson, CFO of Thermo Fisher Scientific, reports an adjustment in his holdings of performance-based restricted stock units due to the company's relative total shareholder return.

Summary

• On February 28, 2025, Stephen Williamson, the Senior VP and CFO of Thermo Fisher Scientific, reported a change in his beneficial ownership of company stock.
• This change involves an adjustment to a performance-based restricted stock unit award granted on February 23, 2022.
• The adjustment resulted in a decrease of 518 shares due to the company's relative total shareholder return (TSR) over the period from January 1, 2022, to December 31, 2024.
• The third tranche of the award, which vested on February 28, 2025, was adjusted downward by 30% because of the company's TSR performance.
• Williamson also reported the disposition of 584.069 shares and 1,032.274 shares at a price of $528.96.
• Following these transactions, Williamson directly owns 33,103.466 shares of common stock and indirectly owns 12,674 shares through a SLAT.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document reports a routine adjustment to executive compensation based on pre-defined performance metrics. While the adjustment resulted in fewer shares being awarded, it reflects the established compensation structure and doesn't necessarily indicate a negative outlook for the company.

Negatives

• The adjustment to the performance-based restricted stock units resulted in a decrease of 518 shares for Stephen Williamson.
• The downward adjustment of 30% to the third tranche of the award indicates that the company's relative total shareholder return (TSR) did not meet the initial expectations.

Industry Context

Executive compensation, particularly performance-based equity, is a common practice in publicly traded companies to align management's interests with those of shareholders. Adjustments to these awards based on TSR are also standard, reflecting the company's performance relative to its peers.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among S&P 500 companies, including Thermo Fisher Scientific's peers in the life sciences and diagnostics industries.
• Companies like Danaher, Agilent Technologies, and Illumina also utilize TSR-based vesting conditions for executive stock awards.
• The specific TSR targets and vesting schedules vary, but the underlying principle of linking executive pay to shareholder value creation is consistent.

Stakeholder Impact

• Shareholders may be interested in the company's TSR performance, as it directly impacts executive compensation.
• Employees holding similar performance-based awards may also be affected by the TSR adjustment.

Key Dates